WO2004071443A3 - Methodes et compositions de modulation de cellules souches - Google Patents

Methodes et compositions de modulation de cellules souches Download PDF

Info

Publication number
WO2004071443A3
WO2004071443A3 PCT/US2004/004007 US2004004007W WO2004071443A3 WO 2004071443 A3 WO2004071443 A3 WO 2004071443A3 US 2004004007 W US2004004007 W US 2004004007W WO 2004071443 A3 WO2004071443 A3 WO 2004071443A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
methods
subject
inhibiting
hsc
Prior art date
Application number
PCT/US2004/004007
Other languages
English (en)
Other versions
WO2004071443A2 (fr
Inventor
Michael P Cooke
Original Assignee
Irm Llc
Michael P Cooke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Michael P Cooke filed Critical Irm Llc
Publication of WO2004071443A2 publication Critical patent/WO2004071443A2/fr
Publication of WO2004071443A3 publication Critical patent/WO2004071443A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes permettant d'inhiber la différenciation de cellules souches et d'augmenter la dose efficace de cellules souches chez un sujet. La différenciation de cellules souches hématopoïétiques peut être inhibée grâce à une méthode consistant à appliquer un polypeptide inhibant la différenciation de cellules souches hématopoïétiques identifié dans la présente invention à une culture in vitro de cellules souches hématopoïétiques, ou à administrer in vivo le polypeptide à un sujet. D'autres méthodes de cette invention consistent d'abord à obtenir une population de cellules souches hématopoïétiques, à introduire dans les cellules un polynucléotide inhibant la différenciation de cellules souches hématopoïétiques, puis à exprimer le polynucléotide inhibant la différenciation de cellules souches hématopoïétiques dans les cellules. De telles cellules souches génétiquement modifiées peuvent être administrées à un sujet, ce qui permet d'augmenter la dose efficace de cellules souches chez le sujet. Cette invention concerne en outre de nouveaux marqueurs moléculaires de cellules souches hématopoïétiques ainsi que des méthodes visant à enrichir les cellules souches hématopoïétiques à l'aide de ces nouveaux marqueurs.
PCT/US2004/004007 2003-02-12 2004-02-11 Methodes et compositions de modulation de cellules souches WO2004071443A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44703003P 2003-02-12 2003-02-12
US60/447,030 2003-02-12

Publications (2)

Publication Number Publication Date
WO2004071443A2 WO2004071443A2 (fr) 2004-08-26
WO2004071443A3 true WO2004071443A3 (fr) 2004-11-25

Family

ID=32869588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/004007 WO2004071443A2 (fr) 2003-02-12 2004-02-11 Methodes et compositions de modulation de cellules souches

Country Status (2)

Country Link
US (1) US20040241856A1 (fr)
WO (1) WO2004071443A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005299379B2 (en) * 2004-10-25 2011-06-09 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
CN101263121A (zh) 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2007055561A1 (fr) * 2005-11-11 2007-05-18 Vascular Biosciences Activité r-ras en régulation vasculaire
JP5341525B2 (ja) 2006-02-14 2013-11-13 セルラント セラピューティクス，インコーポレイティド 造血幹細胞の生着を増強するための方法および組成物
KR101812820B1 (ko) * 2010-01-08 2017-12-27 웨이크 포리스트 유니버시티 헬스 사이언시즈 전달 시스템
CA2828705A1 (fr) 2011-03-07 2012-09-13 Wake Forest University Health Sciences Systeme d'administration
US10898522B2 (en) 2015-08-19 2021-01-26 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451558B1 (en) * 1998-08-03 2002-09-17 Novartis Ag Genes in the control of hematopoiesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN D. ET AL: "Enforced expression of the GATA-3 transcription factor affects cell fate decisions in hematopoiesis", EXPERIMENTAL HEMATOLOGY, vol. 29, 2001, pages 971 - 980, XP002981371 *
COOPER C. ET AL: "Expression of the Id family helix-loop-helix regulators during growth and development in the hematopoietic system", BLOOD, vol. 89, no. 9, 1 May 1997 (1997-05-01), pages 3155 - 3165, XP002981372 *

Also Published As

Publication number Publication date
US20040241856A1 (en) 2004-12-02
WO2004071443A2 (fr) 2004-08-26

Similar Documents

Publication Publication Date Title
Huang et al. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium
AU2003209259A8 (en) Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
WO2008118392A3 (fr) Plate-formes synthétiques de cellules et leurs procédés d'utilisation
EP2727583A3 (fr) Support de médicament et kit de support de médicament permettant d'inhiber la fibrose
MX2008007286A (es) Ingenieria in vivo de superficie celular.
WO2004013093A3 (fr) Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci
WO2006050330A3 (fr) Plaquettes de cellules souches
HK1042242B (zh) 富馬酸二烷基酯的用途
WO2004044142A3 (fr) Cellules souches mesenchymateuses et leurs procedes d'utilisation
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
NZ514888A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
WO2003061591A3 (fr) Cellules endotheliales derivees de cellules souches modifiees pour interrompre l'angiogenese des tumeurs
EP1425390A4 (fr) Materiaux et techniques favorisant la reparation de tissus nerveux
WO2002069896A3 (fr) Apoptose de cellules cancereuses humaines induite par chimiotherapie et augmentee par connexine afin d'inhiber la proliferation de cellules cancereuses
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
MX2007008980A (es) Acidos nucleicos para apoptosis de celulas cancerigenas.
WO2006010070A3 (fr) Compositions et procedes lies a des peptides se liant de facon selective avec des cellules de la leucemie
WO2001007568A3 (fr) Cellules musculaires et leur utilisation dans la reparation cardiaque
DE602006020335D1 (de) Verwendung von parp-1-hemmern
MXPA05006350A (es) Composicion de medio de cultivo, procedimiento de cultivo y mioblastos obtenidos y sus utilizaciones.
WO2001023421A3 (fr) Compositions des proteines du stress et procedes de prevention et de traitement d'un cancer et d'une maladie infectieuse
WO2003033678A3 (fr) Methodes d'utilisation d'inhibiteurs de la desacetylase afin de stimuler la differenciation et la regenerescence cellulaires
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
HK1063198A1 (en) Educated nk t cells and their uses in the manufacture of a medicament for the treatment of immune-related disorders
WO2004071443A3 (fr) Methodes et compositions de modulation de cellules souches

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase